摘要
目的比较吉西他滨联合化疗与吉西他滨单药化疗治疗晚期胰腺癌的疗效。方法 62例晚期胰腺癌患者分为2组:吉西他滨联合化疗组(35例,包括吉西他滨联合奥沙利铂、吉西他滨联合顺铂、吉西他滨联合氟尿嘧啶、吉西他滨联合替吉奥方案),吉西他滨单药化疗组(27例),比较2组化疗的临床疗效及毒副反应。结果 2组总有效率及临床受益率比较差异无统计学意义(P>0.05);联合化疗组毒副反应较单药化疗组高(P<0.05)。结论吉西他滨联合化疗与其单药化疗治疗晚期胰腺癌的临床疗效以及临床受益相似,但前者的毒副反应发生率较高。
Objective To compare the curative effect of gemcitabine combined chemotherapy with gemcitabine single-agent chemotherapy in the treatment of advanced pancreatic cancer. Methods Sixty-two cases of advanced pancreatic cancer were divided into two groups：35 cases of the gemcitabine combined chemotherapy group（a com-bination of gemcitabine and oxaliplatin,gemcitabine and cisplatin gemcitabine and fluorouracil or gemcitabine and S-1）,27 cases of the gemcitabine single-agent chemotherapy group,the curative effect and toxicities of chemotherapy between the two groups were observed comparatively. Results There was no statistical difference in the total re-sponse rate and the clinical benefit rate between the two groups（P ＆gt; 0. 05）. The toxicity incidences of the gemcit-abine combined chemotherapy group were higher than those of the gemcitabine single-agent chemotherapy group. Conclusion The curative effect of gemcitabine combined chemotherapy is similar to gemcitabine single-agent chemotherapy in the treatment of advanced pancreatic cancer,but the former has the higher incidences of toxicities.
出处
《肿瘤基础与临床》
2014年第2期113-115,共3页
journal of basic and clinical oncology
关键词
晚期胰腺癌
吉西他滨
化疗
advanced pancreatic cancer
gemcitabine
chemotherapy
